false
0001493137
0001493137
2026-06-15
2026-06-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported): June
15, 2026
LIFELOC TECHNOLOGIES,
INC.
(Exact name of registrant
as specified in its charter)
| Colorado |
|
000-54319 |
|
84-1053680 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
| 12441 West 49th Ave., Unit 4 |
|
|
| Wheat Ridge, CO |
|
80033 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
(303) 431-9500
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation
FD Disclosure |
On June 15, 2026,
Lifeloc Technologies, Inc. issued a press release titled “Lifeloc Completes SpinDetect™ Disk Production Tooling,
Commissions Cleanroom, and Outlines Staged Commercial Rollout”. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by
reference.
A
copy of the press release is furnished herewith as Exhibit 99.1. Neither the press release nor the contents of any websites linked therein
shall be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor shall be deemed incorporated by reference herein or in any other filing under the Securities
Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 |
Financial Statements and Exhibits. |
| |
|
(d) Exhibits.
| Exhibit No. |
Description |
| |
|
| 99.1 |
Press Release, dated June 15, 2026, issued by the Company |
| |
|
| 104 |
Cover
Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| |
|
SIGNATURES
Pursuant to the
requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| Date: June 15, 2026 |
LIFELOC TECHNOLOGIES, INC. |
| |
|
|
| |
By: |
/s/ Wayne R. Willkomm |
| |
|
Wayne R. Willkomm, PhD.
President and Chief Executive Officer |
Exhibit 99.1
Lifeloc Completes
SpinDetect™ Disk Production Tooling, Commissions Cleanroom, and Outlines Staged Commercial Rollout
WHEAT RIDGE, Colo.,
June 15, 2026 — Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol
and drug testing devices, today provided an update on its SpinDetect™ Centrifugal Drug Analyzer program and its core breath alcohol
business.
Lifeloc has completed
the production mold for the SpinDetect consumable test disks and produced first-article disks, which have undergone initial testing.
Minor mold modifications identified during that testing have been completed, and new production disks are now available for continued
validation. To support validation and initial manufacturing, the company has commissioned a cleanroom equipped with an automated reagent-dispensing
robot — moving the program from development into validation and early production.
Lifeloc intends to
bring SpinDetect to market in deliberate stages. Initial commercialization will target the U.S. forensic testing market and international
markets where permitted; access to the U.S. workplace testing market will follow receipt of FDA clearance. The first commercial product
will be a qualitative pass/fail test for delta-9-THC, the primary psychoactive component of marijuana, with quantitative delta-9-THC
disks and a multi-drug panel expected to follow. Preliminary testing may also support an earlier release into selected lower-complexity,
non-forensic applications such as veterinary testing.
The Company currently
anticipates commercial launch in late 2026 or early 2027. The SpinDetect reader is expected to be offered at an initial U.S. list price
of approximately $7,495, with single-use test disks priced separately.
Reflecting feedback
from law enforcement customers — who have emphasized the importance of a meaningful margin above legal thresholds to support defensible
results — the initial delta-9-THC product is expected to launch at a detection threshold above the 4 ng/mL oral-fluid cutoff referenced
in certain federal guidelines, with the Company intending to pursue lower detection limits following launch. Lifeloc believes the SpinDetect
analyzer’s ability to isolate psychoactive delta-9-THC from its inactive metabolites — distinguishing recent use from prior
use — remains a key differentiator versus existing screening devices.
In its core breath
alcohol business, Lifeloc continues to invest in its L-series platform, including development of an OIML-variant of its LX9 device intended
to broaden addressable international markets while incorporating cost-of-goods improvements. While the SpinDetect platform is designed
to support a range of future assays, the Company’s current development focus is drugs of abuse, and Lifeloc views performance-enhancing
drug testing as the most natural adjacency for future expansion.
“Completing
our disk production tooling and standing up a cleanroom are the steps that turn SpinDetect from a development program into a product,”
said Dr. Wayne Willkomm, President and CEO of Lifeloc. “We’re taking a disciplined, staged approach — prove the technology
in forensic and international markets first, then broaden the drug menu and pursue the workplace and federal opportunities. The ability
to accurately measure impairing delta-9-THC, discriminated from its metabolites, is why we believe this platform can ultimately help
set the standard for roadside and workplace drug testing.”
An updated corporate
presentation is also available on the Company’s investor relations website at https://lifeloc.com/investor.
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer
of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International
customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available
on our web site, www.lifeloc.com.
Forward Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties, including those
described in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission,
that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements
expressed or implied in this press release, including statements about our strategies, expectations about new and existing products,
our ability to fund operations and product development, market demand, acceptance of new and existing products, technologies and opportunities,
development and commercialization timelines, market size and growth, and return on investments in products and market, are based on information
available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly
encouraged to review the section titled “Risk Factors” in our SEC filings.
Phoenix® and Easycal® are
registered trademarks of Lifeloc Technologies, Inc.
SpinDetect™ is a trademark
of Lifeloc Technologies, Inc.
Amy
Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
